公开(公告)号：EP4310095A1

公开(公告)日：2024-01-24

申请号：EP22771444.1

申请日：2022-03-15

Applicant: OSAKA UNIVERSITY ,  KOTAI Biotechnologies, Inc.

Inventor： YAMASAKI, Sho ,  LU, Xiuyuan ,  HOSONO, Yuki ,  ISHIZUKA, Shigenari ,  YAMASHITA, Kazuo ,  SAX, Nicolas Claude Paul

IPC: C07K14/165 ,  A61K35/26 ,  A61K39/215 ,  A61P11/00 ,  A61P31/14 ,  C07K16/10 ,  C12N15/13 ,  C12N15/50

Abstract: Follicular helper T cells specific to SARS-CoV-2 virus are provided. The present disclosure is based on the finding of public TfhTCR specific to spike (S) protein common to various patients, and has identified for the first time a public TCR specific to the SARS-CoV-2 virus and its MHC and antigenic epitopes to promote efficient immune responses, particularly those of B cells that produce neutralizing antibodies. For example, the present disclosure provides a composition containing an epitope specific to SARS-CoV-2 virus for inducing a follicular T cell.

公开(公告)号：EP4310171A1

公开(公告)日：2024-01-24

申请号：EP22771446.6

申请日：2022-03-15

Applicant: OSAKA UNIVERSITY ,  KOTAI Biotechnologies, Inc.

Inventor： YAMASAKI, Sho ,  LU, Xiuyuan ,  HOSONO, Yuki ,  ISHIZUKA, Shigenari ,  YAMASHITA, Kazuo ,  SAX, Nicolas Claude Paul

IPC: C12M1/34 ,  C12Q1/06 ,  C12Q1/6869 ,  G01N33/483 ,  G01N33/53

Abstract: A new medical technique using follicular T cells is provided. The present disclosure is based on the finding of public TfhTCR which is specific to disease factors common to various patients, and provides a method for producing follicular T cells specific to a disease, including a step of identifying a disease-related factor or a part thereof having the ability to induce a follicular T cell reactive with the disease-related factor, a step of inducing the follicular T cell specific to the disease, by using the disease-related factor or a part thereof, and a step of obtaining the follicular T cell specific to the disease.

公开(公告)号：EP3998082A1

公开(公告)日：2022-05-18

申请号：EP20837130.2

申请日：2020-07-09

Applicant: National Cancer Center ,  KOTAI Biotechnologies, Inc.

Inventor： TOGASHI, Yosuke ,  NISHIKAWA, Hiroyoshi ,  YAMASHITA, Kazuo ,  SAX, Nicolas Claude Paul

IPC: A61K39/395 ,  A61P35/00 ,  A61P43/00 ,  C12N5/0783 ,  A61K35/12 ,  A61K35/17

Abstract: The present disclosure provides a specific marker for identifying T cells specifically attacking cancer cells and the utilization of the marker. According to the present disclosure, a marker that has a high specificity for identifying T cells specifically attacking cancer cells is provided. According to the present disclosure, treatment or prevention of cancer in a subject with the use of a cell subpopulation contained in a tumor tissue infiltrating CD106 + T cell population or cells expressing a T cell receptor (TCR) expressed thereby can be provided. According to another embodiment of the present disclosure, a method for producing a cellular medicine can be provided. According to the present disclosure, further, a method that comprises using the amount of a cell subpopulation as an index of the responsiveness of a subject to a cancer immunotherapy can be provided. According to the present disclosure, furthermore, a method for acquiring a tumor specific TCR sequence can be provided.

公开(公告)号：EP4273234A1

公开(公告)日：2023-11-08

申请号：EP21915348.3

申请日：2021-12-29

Applicant: Thyas Co. Ltd. ,  KOTAI Biotechnologies, Inc.

Inventor： KANEKO, Shin ,  GONOTSUBO, Ryosuke ,  OSAWA, Mitsujiro ,  HITOSHI, Yasumichi ,  YAMASHITA, Kazuo ,  SAX, Nicolas Claude Paul

IPC: C12N5/10 ,  A61K35/17 ,  A61K35/545 ,  A61P35/00 ,  C12N5/074 ,  C12N5/0783 ,  C12N15/09 ,  C12N15/12 ,  C12N15/85 ,  C12N15/86

Abstract: [Problems]
To provide a method for producing regenerated T cells via iPS cells into which TCRs isolated from tumor tissue-infiltrating CD106-positive T cells have been introduced.
[Solutions]
Provided is a method for producing regenerated T cells via iPS cells, comprising: 1. A step for preparing cDNAs respectively encoding a TCR α chain and a TCR β chain from individual cells in a CD106-positive T cell population obtained from subjects and having reactivity with a tumor-related antigen; 2. A step for reprogramming peripheral blood mononuclear cells which are obtained from the subjects and from which B cells and T cells have been removed or T cells into iPS cells, and selecting iPS cell clones having high efficiency of differentiation into T cells from the obtained iPS cells; 3. A step for introducing the cDNAs into the iPS cell clones, hematopoietic stem cells differentiated from the iPS cell clones, immature T cells differentiated from the hematopoietic stem cells, or mature T cells differentiated from the immature T cells; and 4. A step for performing the differentiation of the iPS cell clones having the cDNAs introduced therein, the hematopoietic stem cells or the immature T cells which have been obtained in step 3 into mature T cells and the proliferation of the mature T cells.